Exploring the Role of Vif Antagonists in Preventing Sexual HIV Transmission

Project: Research project

Description

DESCRIPTION (provided by applicant): Since it has proven difficult to develop a vaccine against HIV-1, the major cause of the AIDS pandemic, the research community has shifted some of its focus to the development of topical microbicides. Since both the vaginal and rectal tract are portals of HIV-1 entry, topical microbicides suitable to protect both sites need to be developed. In this grant, we focus on a novel mechanism that has not previously been explored for HIV prevention. In 2002, it was found that the cellular target of the HIV-1 protein Vif is APOBEC3G (A3G). A3G is an enzyme of the AID/APOBEC family, characterized by the targeted deamination of cytosine to generate uracil within DNA. APOBEC3G plays an important role in retroviral defense by acting on viral reverse transcripts and mediates numerous critical immune responses. We believe that A3G is an important innate retroviral defense mechanism in the vaginal and rectal tract. By using inhibitors of the viral protein Vif, the Vif-APOBEC3G interaction is blocked and APOBEC3G is not degraded by the proteosome. As a consequence, fatal hypermutations are introduced into the viral cDNA transcripts and HIV is rendered incompetent for replication. Our grant has four specific aims: Specific Aim 1: Explore the role of the restriction factor A3G in mucosal tissues of the vaginal and rectal tract Specific Aim 2: Examine whether RN18 and its analogs are active in microbicide cell-based assays and ex vivo explant HIV transmission models Specific Aim 3: Vaginal humanized BLT mouse model testing of promising Vif inhibitor candidates Specific Aim 4: Macaque microbicide model testing of promising Vif inhibitor candidates It is expected that these studies will define the role of A3G in the vaginal and rectal tract and whether inhibitors of the viral Vif protein can prevent sexual transmission of HIV.
StatusFinished
Effective start/end date7/1/105/31/17

Funding

  • National Institutes of Health: $486,167.00
  • National Institutes of Health: $413,403.00
  • National Institutes of Health: $425,852.00
  • National Institutes of Health: $210,914.00
  • National Institutes of Health: $65,788.00
  • National Institutes of Health: $255,729.00

Fingerprint

HIV
Local Anti-Infective Agents
Organized Financing
Viral Proteins
Anti-Infective Agents
HIV-1
vif Gene Products
Deamination
Uracil
Cytosine
Macaca
Pandemics
Mucous Membrane
Acquired Immunodeficiency Syndrome
Vaccines
Complementary DNA
DNA
Research
APOBEC Deaminases
Human immunodeficiency virus 1 vif protein

ASJC

  • Medicine(all)
  • Immunology and Microbiology(all)